Gonorrhea Diagnostics Market - Forecast(2023 - 2028)
Gonorrhea Diagnostics Market Overview
The Gonorrhea Diagnostics Market is estimated to reach $13.6 billion by 2028, growing at a CAGR of 8.9% over the forecast period 2023-2028. Gonorrhea is a sexually transmitted infection afflicted by a bacterium that can affect both genders. Most often, gonorrhea impacts the urethra, rectum or throat. The recommended treatment for gonorrhea includes fluoroquinolone and ciprofloxacin. Cephalosporins, ceftriaxone (intramuscular) or cefixime (oral) are the recommended alternatives. However, recent audit data reveal other cephalosporins, including cefuroxime (intramuscular or often oral), that are currently being used to treat gonorrhea. Gonorrhea can also infect the cervix in females. Most frequently, gonorrhea is spread through vaginal, oral or anal intercourse. But after childbirth, newborns of infected mothers can contract the disease. Gonorrhea most frequently damages the eyes in infants. According to the Women’s Health & STIs article, for vaginal infections, traditional diagnostics leave up to 40% of women with vaginitis undiagnosed after an initial clinical visit.
Gonorrhea Diagnostics Market Report Coverage
The report: “Gonorrhea Diagnostics Market – Forecast (2023-2028)” by IndustryARC, covers an in-depth analysis of the following segments in the Gonorrhea Diagnostics Market.
- Geographically, North America dominates the Gonorrhea Diagnostics Market in 2022, owing to the rising awareness about the disease.
- The key factor anticipated to drive the Gonorrhea Diagnostics industry in the future is the engagement of multiple sex partners and rapidly changing lifestyles.
- The growth rate of the Gonorrhea diagnostics market size is anticipated to be steady, owing to an increase in hospitals, commercial labs and improved diagnostic methods that are quicker and more cost-effective.
- A detailed analysis of strengths, weaknesses, opportunities and threats would be provided in the Gonorrhea Diagnostics Market Report.
Gonorrhea Diagnostics Market Segment Analysis – by Diagnostic Type:
Based on Diagnostic Type, Gonorrhea Diagnostics Market is further segmented into Flow Cytometry, Diagnostic Imaging, Gel Micro-droplets, Artificial Intelligence, Chromatography, Differential Light Scattering (DLS), Liposomes, Monoclonal Antibodies, Molecular Diagnostics Tests and Others. The Molecular Diagnostics segment held the largest share of the Gonorrhea diagnostics market in 2022, owing to the advantages associated with it such as ease of performing the procedure, high accuracy and cost for the performance. It is often necessary to use monoclonal antibody techniques to determine between gonorrhea and other illnesses that have overlapping symptoms, which helps in expanding the Gonorrhea Diagnostics market size.
However, the Flow Cytometry segment is anticipated to grow at the fastest CAGR of 9.5% over the forecast period 2023-2028. This is due to modern techniques such as artificial intelligence and diagnostic imaging, which are in the testing phases. Traditional methods of diagnosis are predicted to be replaced by newer technologies like flow cytometry for faster and more accurate illness detection and change the market scenario for the Gonorrhea Diagnostics industry in the future.
Gonorrhea Diagnostics Market Segment Analysis – by End-user:
Based on end-users, the Gonorrhea Diagnostics market is further segmented into hospitals, laboratory testing, diagnostic centers, clinics, point-of-care testing and others. The Point-of-care Testing segment held the largest share of the Gonorrhea diagnostics market in 2022, as the rates of gonococcal infection and associated costs of untreated infections continued to increase. According to the Centers for Disease Control (CDC), the rate of gonococcal infection has increased by 74% despite the availability of highly sensitive and specific laboratory-based molecular diagnostics tools for the detection of these Sexually Transmitted Infections (STIs).
However, the Laboratory Testing segment is anticipated to grow at the fastest CAGR of 9.3% over the forecast period 2023-2028, as most of the cases of diagnostic testing are carried out in the labs, which is anticipated to further fuel the Gonorrhea Diagnostics market.
Gonorrhea Diagnostics Market Segment Analysis – by Geography:
Based on Geography, the North American Gonorrhea Diagnostics Market accounted for 37% of the revenue share in 2022, owing to the well-developed healthcare infrastructure and favorable government policies regarding the diagnosis and treatment of Sexually Transmitted Diseases (STD). According to the Centers for Disease Control (CDC), there are around 400,000 cases of gonorrhea reported each year in the U.S. The high awareness level about the disease and favorable reimbursement policies are the factors anticipated to expand the Gonorrhea diagnostics market size in the region.
However, the Asia-Pacific region is estimated to grow at the fastest CAGR during the forecast period 2023-2028, owing to the increasing cases of the disease in the region and the number of unmet demands in the market for efficient diagnoses and treatments.
Gonorrhea Diagnostics Market Drivers
Increasing Rates of Sexually Transmitted Infections (STIs):
The Gonorrhea Diagnostics market for Sexually Transmitted Diseases (STD) testing is growing as a result of increased public awareness and patient education. Additionally, it is projected that an expansion of government initiatives, an improvement in patient awareness through education programs and an increase in STI prevalence internationally would fuel market expansion. The prevalence and incidence of STIs have accelerated. According to WHO, more than 1 million Sexually Transmitted Infections (STIs) are acquired every day worldwide, the majority of which are asymptomatic.
The Rising Prevalence and Awareness of the Disease:
Gonorrhea prevalence rates are rising as a result of a number of factors, including increased public awareness, better access to healthcare, diagnostic test availability, patterns of resistance, reporting practices and others. Although gentamicin should not be used as the first line of treatment for gonorrhea, it may still be beneficial for some people. They may be individuals with isolated genital infections, people who are allergic to or intolerant to ceftriaxone or ones who have an infection that is resistant to ceftriaxone. In the past, men were more likely than women to contract gonorrhea and get treated through chromatography diagnostics. Over the past few years, the prevalence rate of gonorrhea is higher in women than in men. According to the Centers for Disease Control (CDC), it is estimated that among these 8,20,000 new cases, 70% of the population would be between the ages of 15 and 24. The Centers for Disease Control (CDC) reports that gonorrhea is more likely to affect women over the age of 25.
Gonorrhea Diagnostics Market Challenge
Rise of Antibiotic-resistant Gonococcal Strains:
The Centers for Disease Control (CDC) restricted the use of fluoroquinolones in the U.S. as a result of the spread of fluoroquinolone-resistant Neisseria gonorrhoeae, leaving cephalosporin as the main risk-free agent for gonorrheal infection. As per the Centers for Disease Control (CDC), there are around 400,000 cases of gonorrhea reported each year in the U.S. and approximately 8,20,000 new gonorrhea infections might occur each year. Out of these, about 30% of new infections are resistant to at least one antibiotic intended to treat the infection. This narrows the range of therapy options available to patients, thereby hindering Gonorrhea Diagnostics market growth.
Gonorrhea Diagnostics Industry Outlook:
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Gonorrhea Diagnostics Industry. The top 10 companies in the Gonorrhea Diagnostics Industry are:
- Abbott Laboratories
- Bayer AG
- Merck & Co., Inc.
- Agilent Technologies
- Biomerieux SA
- Danaher Corporation
- Thermo Fisher Scientific
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- In October 2022, Bayer and the Bill & Melinda Gates Foundation are jointly funding pre-clinical research in the area of novel non-hormonal contraception. This collaboration with the Bill & Melinda Gates Foundation would contribute to expanding access to contraceptive options that address the unmet needs of women worldwide.
- In September 2022, Abbott launched its European Amplatzer™ Talisman™ PFO Occlusion System to treat people who have had a stroke and are at risk of getting another one and have a Patent Foramen Ovale (PFO), a hole in the heart that doesn't shut after birth.
- In August 2022, Danaher Corporation announced the completion of its acquisition of Aldevron. It would operate as a standalone operating company and brand within Danaher's Life Sciences segment.
Diagnostic Imaging Services Market - Industry Analysis, Market Size, Market Share, Trend Analysis, Application Analysis and Forecast Analysis.
Report Code: HCR 0248
E. Coli Testing Market - Industry Analysis, Market Size, Market Share, Trend Analysis, Application Analysis and Forecast Analysis.
Report Code: HCR 0285
Infectious Disease Testing Market - Industry Analysis, Market Size, Market Share, Trend Analysis, Application Analysis and Forecast Analysis.
Report Code: HCR 0085
For more Lifesciences and Healthcare Market reports, please click here